Tg Therapeutics: KDJ Death Cross, Bearish Marubozu on 15-Minute Chart

The 15-minute chart for Tg Therapeutics recently triggered a KDJ Death Cross and a Bearish Marubozu on October 1, 2025 at 14:00. This suggests a shift in the momentum of the stock price towards a downward trend, with potential for further decreases in value. The sellers appear to be in control of the market, and it is likely that the bearish momentum will continue.

New York - Tg Therapeutics, Inc. (NASDAQ: TGTX) has recently witnessed a significant shift in its stock price momentum, with a KDJ Death Cross and a Bearish Marubozu pattern triggering on October 1, 2025, at 14:00. This technical indicator suggests a potential downward trend in the stock price, with sellers appearing to be in control of the market TG Therapeutics, Inc. - New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression after 6 Years of Continuous BRIUMVI Treatment^[1].

The stock's recent technical signals are accompanied by updated clinical data from the company's ongoing trials, which were presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. Bruce Cree, MD, PhD, MAS, from the University of California, San Francisco, highlighted the six-year data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS). The data demonstrated compelling evidence of durable efficacy, with sustained protection against relapses and disability progression .

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, stated that nearly 90% of patients on BRIUMVI remained free from disability progression after six years of continuous treatment. This finding, coupled with one of the lowest relapse rates ever reported in a Phase 3 RMS study, reinforces the company's confidence in BRIUMVI's potential .

Despite the positive clinical data, the stock's technical indicators suggest a bearish trend, which could lead to further decreases in value. Investors should closely monitor the market for any signs of a reversal in momentum. The company's future performance will depend on its ability to navigate both the clinical and market landscapes effectively.

References

TG Therapeutics, Inc. - New Data for BRIUMVI Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression after 6 Years of Continuous BRIUMVI Treatment^[1] https://www.marketscreener.com/news/tg-therapeutics-inc-new-data-for-briumvi-demonstrate-89-9-of-patients-with-relapsing-multiple-s-ce7d58d3d981ff23
https://www.marketscreener.com/news/tg-therapeutics-inc-new-data-for-briumvi-demonstrate-89-9-of-patients-with-relapsing-multiple-s-ce7d58d3d981ff23